Department of Internal Medicine, Circulatory and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki, Japan.
Department of Pharmacy, University of Miyazaki Hospital, Japan.
Intern Med. 2021 Feb 1;60(3):423-429. doi: 10.2169/internalmedicine.5317-20. Epub 2020 Sep 19.
We herein report the cytokine expression at different stages for three patients who developed cardiac complications after immune checkpoint inhibitor (ICI) therapy. Case 1 with biopsy-proven myocarditis showed increased levels of interleukin (IL)-8, monocyte chemotactic and activating factor, and granulocyte macrophage colony-stimulating factor (GM-CSF) when he developed Takotsubo cardiomyopathy. Case 2 with subclinical myocarditis showed predominant activation of IL-8 during the progressive clinical course. Case 3 with cytokine-releasing syndrome showed substantial activations of IL-6, IL-8, GM-CSF, and interferon-γ. Our data suggest the development of unique cytokine activation in individual patients with cardiac complications after ICI therapy.
我们在此报告了 3 例免疫检查点抑制剂（ICI）治疗后发生心脏并发症患者在不同阶段的细胞因子表达情况。1 例经活检证实的心肌炎患者在发生 Takotsubo 心肌病时，白细胞介素（IL）-8、单核细胞趋化因子和激活因子以及粒细胞巨噬细胞集落刺激因子（GM-CSF）水平升高。2 例亚临床心肌炎患者在进行性临床病程中主要表现为 IL-8 激活。3 例细胞因子释放综合征患者表现出 IL-6、IL-8、GM-CSF 和干扰素-γ 的显著激活。我们的数据表明，ICI 治疗后发生心脏并发症的患者存在独特的细胞因子激活。
